Cancer detection technology developer Verisante (Vancouver, BC, Canada) will expand its exclusive agreement with medical device distributor bo pharma BV (Ankeveen, The Netherlands). Under the agreement, bo pharma will distribute Verisante's Aura optical system for skin lesion evaluation in Sweden, Norway, Denmark, Finland, and Iceland along with Belgium, The Netherlands, and Luxembourg.
The Aura system, which uses Raman spectroscopy, noninvasively evaluates skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma, and basal cell carcinoma before making a final decision to biopsy. The device will help to automate the current process of diagnosis, allowing rapid scanning of skin lesions on at-risk individuals. What's more, the system received European CE Mark approval last year.
-----
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!